Vir Biotechnology Dirección

Dirección controles de criterios 1/4

El CEO de Vir Biotechnology es Marianne De Backer , nombrado en Apr 2023, tiene una permanencia de 1.58 años. compensación anual total es $39.49M, compuesta por 1.7% salario y 98.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.052% de las acciones de la empresa, por valor de $558.99K. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 5.8 años, respectivamente.

Información clave

Marianne De Backer

Chief Executive Officer (CEO)

US$39.5m

Compensación total

Porcentaje del salario del CEO	1.7%
Permanencia del CEO	1.6yrs
Participación del CEO	0.05%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Nov 05

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Nov 04

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Sep 08

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Aug 03

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jul 17

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

May 05

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Aug 07

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Jul 24

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Feb 28

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 07

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Marianne De Backer en comparación con los beneficios de Vir Biotechnology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$533m
Jun 30 2024	n/a	n/a	-US$483m
Mar 31 2024	n/a	n/a	-US$539m
Dec 31 2023	US$39m	US$675k	-US$615m

Compensación vs. Mercado: La compensación total de Marianne($USD39.49M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.16M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Marianne con los resultados de la empresa.

CEO

Marianne De Backer (55 yo)

1.6yrs

Permanencia

US$39,491,495

Compensación

Dr. Marianne De Backer, MSc, Ph. D. MBA, served as Independent Director at Kronos Bio, Inc. from January 25, 2021 to June 2023. Dr. De Backer served as Executive Vice President, Head of Global Business Dev...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Marianne De Backer	CEO & Director	1.6yrs	US$39.49m	0.052% $ 559.0k
Ann Hanly	Executive VP & Chief Technology Officer	3.7yrs	US$3.11m	0.029% $ 312.1k
Jeff Calcagno	Executive VP & Chief Business Officer	1.5yrs	US$4.54m	0.00022% $ 2.4k
Klaus Frueh	Co-Founder & Scientific Advisor	8.8yrs	US$177.66k	sin datos
Lawrence Corey	Co-Founder & Scientific Advisor	8.8yrs	sin datos	sin datos
Louis Picker	Co-Founder & Scientific Advisor	no data	sin datos	sin datos
Jason O'Byrne	Executive VP & CFO	less than a year	sin datos	sin datos
Brent Sabatini	Senior VP	1.8yrs	sin datos	0.021% $ 223.5k
Jennifer Towne	Executive VP & Chief Scientific Officer	less than a year	sin datos	sin datos
Heather Armstrong	Vice President of Investor Relations	no data	sin datos	sin datos
Vanina de Verneuil	Executive VP	2.2yrs	sin datos	0.041% $ 447.8k
Arran Attridge	Senior Vice President of Corporate Communications	less than a year	sin datos	sin datos

1.7yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VIR no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Marianne De Backer	CEO & Director	1.6yrs	US$39.49m	0.052% $ 559.0k
Klaus Frueh	Co-Founder & Scientific Advisor	5.8yrs	US$177.66k	sin datos
Lawrence Corey	Co-Founder & Scientific Advisor	no data	sin datos	sin datos
Louis Picker	Co-Founder & Scientific Advisor	no data	sin datos	sin datos
Robert Taylor Nelsen	Independent Director	8.6yrs	US$454.90k	0.44% $ 4.8m
Robert J. More	Independent Director	8.2yrs	US$474.90k	0.028% $ 304.1k
Vicki Sato	Independent Chairman	7.9yrs	US$502.26k	0.96% $ 10.4m
George Scangos	Director	7.8yrs	US$688.20k	2.78% $ 30.1m
Thomas Daniel	Scientific Advisor	5.8yrs	US$23.92k	sin datos
Charles Rice	Scientific Advisor	no data	sin datos	sin datos
Jeffrey Hatfield	Independent Director	3.9yrs	US$472.17k	0.017% $ 187.2k
Sona Saira Ramasastry	Independent Director	5.2yrs	US$476.51k	0.011% $ 115.0k

5.8yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de VIR se considera experimentada (5.8 años de antigüedad promedio).

Vir Biotechnology Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Vir Biotechnology, Inc. Announces Executive Appointments

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

CEO & Director recently sold US$690k worth of stock

Director notifies of intention to sell stock

Recent updates

Vir Biotechnology, Inc. Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology, Inc. Announces Positive End-Of-T Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the March Study at AASLD The Liver Meeting

Consensus EPS estimates fall by 18%

New minor risk - Shareholder dilution

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Price target decreased by 41% to US$18.43

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

New major risk - Revenue and earnings growth

Price target increased by 8.2% to US$33.29

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Vir Biotechnology, Inc. Announces Executive Appointments

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 18%, EPS upgraded

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Vir Biotechnology, Inc.(NasdaqGS:VIR) dropped from Russell 2000 Value-Defensive Index

Vir Biotechnology, Inc. Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

New minor risk - Share price stability

Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Consensus revenue estimates increase by 78%

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

CEO & Director recently sold US$690k worth of stock

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Director notifies of intention to sell stock

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Director notifies of intention to sell stock

Price target increased by 12% to US$29.50

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

Price target decreased by 32% to US$18.00

Vir Biotechnology, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target decreased by 10% to US$26.50

Sticking With Vir Biotechnology

Price target decreased by 9.2% to US$29.75

Price target decreased by 9.2% to US$29.75

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s the Liver Meeting® 2023

Vir Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Biomedical Advanced Research and Development Authority Awards Funding to Vir Biotechnology, Inc. to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

New major risk - Revenue and earnings growth

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Consensus revenue estimates fall by 36%

Vir Biotechnology, Inc. Announces Topline Data from Phase 2 Peninsula Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

Price target decreased by 24% to US$36.38

New minor risk - Share price stability

Independent Chairman notifies of intention to sell stock

Vir Biotechnology, Inc. Announces the Appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, Effective July 10, 2023

Vir Biotechnology, Inc. Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

Independent Director notifies of intention to sell stock

Vir Biotechnology, Inc. Elects Elliott Sigal as Director

Vir Biotechnology, Inc. Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

Vir Biotechnology, Inc. Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNa and an NRTI

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Technology Officer recently sold US$60k worth of stock